Editorial
doi: 10.1378/chest.113.2.261.
Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?
- PMID: 9498932
- DOI: 10.1378/chest.113.2.261
Item in Clipboard
Editorial
Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?
Chest.
1998 Feb.
Free article
No abstract available
Similar articles
-
Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.Pharmacoeconomics. 2004;22(10):671-83. doi: 10.2165/00019053-200422100-00005. Pharmacoeconomics. 2004. PMID: 15244492
-
Barriers to the use of warfarin: potential solutions.J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e. J Interv Card Electrophysiol. 2004. PMID: 14739735 No abstract available.
-
Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.Ann Pharmacother. 2012 Dec;46(12):1609-16. doi: 10.1345/aph.1Q472. Epub 2012 Nov 13. Ann Pharmacother. 2012. PMID: 23150608
-
[Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].Praxis (Bern 1994). 2014 Jun 18;103(13):785-6. doi: 10.1024/1661-8157/a001681. Praxis (Bern 1994). 2014. PMID: 24938162 Review. German. No abstract available.
-
Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.Neurologist. 2012 Mar;18(2):102-7. doi: 10.1097/NRL.0b013e318247bcb6. Neurologist. 2012. PMID: 22367842 Review.
Cited by
-
Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.Pharmacoeconomics. 2004;22(10):671-83. doi: 10.2165/00019053-200422100-00005. Pharmacoeconomics. 2004. PMID: 15244492
-
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758. JAMA. 2008. PMID: 19050195 Free PMC article.
-
Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.Health Serv Res. 2003 Aug;38(4):1051-63. doi: 10.1111/1475-6773.00162. Health Serv Res. 2003. PMID: 12968816 Free PMC article.
-
Barriers to the use of warfarin: potential solutions.J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e. J Interv Card Electrophysiol. 2004. PMID: 14739735 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
